NCT01862367 - Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 17, 2013

Primary Completion Date

June 26, 2019

Study Completion Date

June 26, 2019

Conditions

Congenital Bleeding DisorderCongenital FXIII Deficiency

Interventions

DRUG

catridecacog

No treatment given. All patients enrolled in this observational study will receive their medication through usual commercial channels.

Trial Locations (17)

4012

Novo Nordisk Investigational Site, Debrecen

16147

Novo Nordisk Investigational Site, Genova

28046

Novo Nordisk Investigational Site, Madrid

29011

Novo Nordisk Investigational Site, Málaga

30322

Novo Nordisk Investigational Site, Atlanta

33607

Novo Nordisk Investigational Site, Tampa

43205

Novo Nordisk Investigational Site, Columbus

43500

Novo Nordisk Investigational Site, Tortosa

44106

Novo Nordisk Investigational Site, Cleveland

48201

Novo Nordisk Investigational Site, Detroit

55404

Novo Nordisk Investigational Site, Minneapolis

66100

Novo Nordisk Investigational Site, Chieti

92868

Novo Nordisk Investigational Site, Orange

A1B 3V6

Novo Nordisk Investigational Site, St. John's

M5G 1X8

Novo Nordisk Investigational Site, Toronto

08035

Novo Nordisk Investigational Site, Barcelona

AB25 2ZN

Novo Nordisk Investigational Site, Aberdeen